← Back to Search

Targeted Therapy

Experimental Group for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Led By Devalingam Mahalingam, MD
Research Sponsored by Devalingam Mahalingam
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG Performance Status of 0-1 within 14 days prior to registration.
Histological or cytological confirmation of pancreatic cancer per AJCC, 8th edition.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will test a new cancer drug, sotorasib, to see if it is safe and effective when combined with standard chemotherapy for treating pancreatic cancer that has progressed after first-line treatment.

Eligible Conditions
  • Pancreatic Cancer
  • KRAS Mutation

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Assess Adverse Events
Disease Control Rate (DCR)
Duration of Response (DoR)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental GroupExperimental Treatment6 Interventions
Patients will either receive a combination of: Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV) OR Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel *The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sotorasib
FDA approved
Paclitaxel
FDA approved
Leucovorin
FDA approved

Find a Location

Who is running the clinical trial?

AmgenIndustry Sponsor
1,355 Previous Clinical Trials
1,384,071 Total Patients Enrolled
Devalingam MahalingamLead Sponsor
1 Previous Clinical Trials
Devalingam Mahalingam, MDPrincipal InvestigatorNorthwestern University Feinberg School of Medicine
2 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has enrollment begun for this particular clinical experiment?

"Affirmative, the information on clinicaltrials.gov confirms that this examination is recruiting participants. It was first released on September 13th 2022 and updated most recently on September 22nd 2022. 59 people need to be sourced from a single medical institution for participation in the trial."

Answered by AI

How many participants have registered for this research initiative?

"Affirmative. Per the details hosted on clinicaltrials.gov, this medical trial is actively seeking out patients to join in their research endeavour; first posted on September 13th 2022 and last updated a few days later. They are looking for 59 volunteers from one single location."

Answered by AI
~0 spots leftby Mar 2025